NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has prepared a third supplementary prospectus (the “Supplement Prospectus”) to the prospectus regarding invitation to subscribe for units (the “Rights Issue”) which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) on 26 April 2023, and published by the Company on the same day (the “Prospectus”) and the supplement prospectuses that were approved and registered by the Swedish Financial Supervisory Authority on 9 May 2023 (the “Supplement Prospectus 1”) and 12 May 2023 (the “Supplement Prospectus 2”), respectively.
The Supplement Prospectus has been prepared as Alligator on 18 May 2023 through a press release announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s drug candidate mitazalimab for the treatment of pancreatic cancer, which is a key milestone for the continued development of the drug candidate and confers significant benefits in the form of marketing exclusivity and cost savings during development following approval.
The Supplement Prospectus has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”) and was approved by the Swedish Financial Supervisory Authority on 24 May 2023. The Supplement Prospectus is to be considered a part of, and shall be read in connection with, the Prospectus, the Supplement Prospectus 1 and the Supplement Prospectus 2. The Prospectus, the Supplement Prospectus 1, the Supplement Prospectus 2 and the Supplement Prospectus (together the ”Prospectuses”) are available on the Company’s, Aktieinvest FK AB’s and Redeye AB’s respective websites (www.alligatorbioscience.com, www.aktieinvest.se and www.redeye.se), and will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se).
For complete terms and conditions and other information regarding the Rights Issue, please refer to the Prospectuses.
DNB Markets, a part of DNB Bank ASA, Sweden Branch and Redeye AB act as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB acts as legal adviser to Alligator in connection with the Rights Issue. Aktieinvest FK AB acts as the issuing agent in connection with the Rights Issue.